Literature DB >> 19086598

Management of myelodysplastic syndromes: 2008 update.

Bart L Scott1, Eli Estey.   

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19086598      PMCID： PMC2647329     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  38 in total

1.  Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes.

Authors:  Noritaka Yamaguchi; Yoshikazu Ito; Kazuma Ohyashiki
Journal:  Ann Hematol       Date:  2005-02-12       Impact factor: 3.673

2.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

3.  Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.

Authors:  R S Negrin; D H Haeuber; A Nagler; L C Olds; T Donlon; L M Souza; P L Greenberg
Journal:  Ann Intern Med       Date:  1989-06-15       Impact factor: 25.391

4.  The WHO classification of MDS does make a difference.

Authors:  Robert B Howe; Anna Porwit-MacDonald; Robert Wanat; Ramin Tehranchi; Eva Hellström-Lindberg
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

5.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

6.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.

Authors:  M Stadler; U Germing; K-O Kliche; K M Josten; R Kuse; W-K Hofmann; H Schrezenmeier; J Novotny; O Anders; H Eimermacher; W Verbeek; H-H Kreipe; H Heimpel; C Aul; A Ganser
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

7.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.

Authors:  Yogen Saunthararajah; Ryotaro Nakamura; Robert Wesley; Qiong J Wang; A John Barrett
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

8.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

Authors:  E Hellström-Lindberg; T Ahlgren; Y Beguin; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; L Kanter-Lewensohn; O Linder; M Luthman; E Löfvenberg; H Nilsson-Ehle; J Samuelsson; J M Tangen; I Winqvist; G Oberg; A Osterborg; A Ost
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

9.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors:  Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

10.  Platelet function and its clinical significance in the myelodysplastic syndromes.

Authors:  Aliza Zeidman; Nir Sokolover; Zinaida Fradin; Amos Cohen; Ophra Redlich; Moshe Mittelman
Journal:  Hematol J       Date:  2004
View more
  4 in total

Review 1.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 2.  Myocardial remodeling: cellular and extracellular events and targets.

Authors:  Jennifer A Dixon; Francis G Spinale
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

3.  Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.

Authors:  Roland B Walter; Stephanie J Lee; Kelda M Gardner; Xiaoyu Chai; Kathleen Shannon-Dorcy; Frederick R Appelbaum; Elihu H Estey
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

4.  New treatments for myelodysplastic syndromes.

Authors:  Francesco D'Alò; Mariangela Greco; Marianna Criscuolo; Maria Teresa Voso
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-11       Impact factor: 2.576
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.